Are ICER publications having an impact on drug price acceptability in the US?
The Institute for Clinical and Economic Review (ICER) is a US lobby group that looks at the clinical benefit of value-added drugs and recommends “cost-effective” prices. Their definition of cost-effectiveness is not a hard barrier, such as the one used by NICE in the UK, but is a range of thresholds, the highest of which is 200 000 USD per quality-adjusted life year (QALY). Pharmaceutical executives are interested in whether ICER’s publications are impacting their drugs’ price acceptability.
Back to White Papers